Active Ingredient History
Mercaptopurine, marketed under the brand name Purinethol among others, is a medication used for cancer and autoimmune diseases. Mercaptopurine competes with hypoxanthine and guanine for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) and is itself converted to thioinosinic acid (TIMP). This intracellular nucleotide inhibits several reactions involving inosinic acid (IMP), including the conversion of IMP to xanthylic acid (XMP) and the conversion of IMP to adenylic acid (AMP) via adenylosuccinate (SAMP). In addition, 6-methylthioinosinate (MTIMP) is formed by the methylation of TIMP. Both TIMP and MTIMP have been reported to inhibit glutamine-5-phosphoribosylpyrophosphate amidotransferase, the first enzyme unique to the de novo pathway for purine ribonucleotide synthesis. Experiments indicate that radiolabeled mercaptopurine may be recovered from the DNA in the form of deoxythioguanosine. Some mercaptopurine is converted to nucleotide derivatives of 6-thioguanine (6-TG) by the sequential actions of inosinate (IMP) dehydrogenase and xanthylate (XMP) aminase, converting TIMP to thioguanylic acid (TGMP). PURINETHOL (mercaptopurine) is indicated for maintenance therapy of acute lymphatic (lymphocytic, lymphoblastic) leukemia as part of a combination regimen. The response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient (pediatric or adult). NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Astrocytoma (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Burkitt Lymphoma (Phase 1/Phase 2)
Cardiotoxicity (Phase 3)
Colitis (Phase 2)
Colitis, Ulcerative (Phase 3)
Crohn Disease (Phase 4)
Cytokines (Phase 2)
Down Syndrome (Phase 3)
Drug Evaluation (Phase 2)
Drugs, Investigational (Phase 4)
Geriatrics (Phase 3)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Healthy Volunteers (Phase 1)
Hermanski-Pudlak Syndrome (Phase 2)
Histiocytosis, Langerhans-Cell (Phase 3)
Inflammatory Bowel Diseases (Phase 4)
Leukemia (Phase 3)
Leukemia, B-Cell (Phase 2)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 4)
Leukemia, Lymphoid (Phase 4)
Leukemia-Lymphoma, Adult T-Cell (Phase 1/Phase 2)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 4)
Leukemia, Promyelocytic, Acute (Phase 3)
Leukemia, T-Cell (Phase 2/Phase 3)
Lupus Erythematosus, Systemic (Phase 2)
Lymphocytes (Phase 2)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 1/Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 3)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 3)
Mucositis (Phase 3)
Myeloproliferative Disorders (Phase 3)
Neoplasms (Phase 2)
Neutropenia (Phase 2)
Oligodendroglioma (Phase 2)
Ovarian Neoplasms (Phase 2)
Plasmacytoma (Phase 2)
Testicular Neoplasms (Phase 3)
Thrombocytopenia (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
